Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Trends That Matter for Cystic Fibrosis

Posted by Matt Breese on Feb 1, 2018

Find me on:

new-blog-image-class.png

In our weekly Trends that Matter series, we provide infographics, articles and recent news from health care influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is cystic fibrosis. 

According to our recent payer coverage analysis for cystic fibrosis, combined with news from key health care influencers, market access is shifting in this drug landscape. We saw a reduction in both step therapy policies and piror authorizations.

Here are some recent trends:

  • A Lack of Adherence: A recent study notes that only about 50% of patients with cystic fibrosis adhere to chronic pulmonary medication, while poor adherence is associated with worse health outcomes. Organizations are pushing to develop and approve methods to monitor patient adherence. 
  • A Network of Patient Support: Recent social media posts and general news point out the wealth of information provided to both cystic fibrosis patients and prescribers through organizations like the Cystic Fibrosis Foundation. This type of easy-to-access information, like clinical trial finders, sets the stage for similar informational sources in other disease areas.
  • Specialty Pharmacy Involvement: With a highly managed class of treatments like cystic fibrosis, the ability to accelerate the time-to-treatment for patients is essential. Pharma and providers partner with specialty pharmacies to ensure the medications are in stock and patients are at a high adherence rate. 

To learn more about this topic, download MMIT's Reality Check by clicking on the button below: 

View Reality Check 

Topics: Specialty, Industry Trends